The average stand-alone Medicare drug plan premium went down this year, from $39 a month to $36, according to KFF’s analysis of CMS enrollment data. Meanwhile the share of stand-alone plan members facing no drug deductible collapsed from 15% to 4%. Both things are true at once, and the connection between them is worth understanding before open enrollment opens on October 15. The Medicare Part D 2026 changes did not make prescription coverage cheaper. They rearranged who absorbs the cost, and the premium is now the least informative number on the page.
A cap does not lower a price, it reassigns one
Start with what the $2,100 out-of-pocket cap actually is. Once your own spending on covered Part D drugs reaches $2,100 in a calendar year, you pay nothing more for the rest of the year. That is a genuine protection and a large one, particularly for anyone on a specialty drug, where before 2025 there was no ceiling at all and you kept paying a percentage forever.
But the drug still costs what it costs. If a medication runs $60,000 a year and you stop paying at $2,100, someone is carrying the other $57,900. Under the redesigned benefit that someone is largely the insurance company, with the manufacturer picking up a share through required discounts. Plans that used to hand their sickest members off to a federal catastrophic backstop now keep that risk on their own books.
An insurer handed a permanent increase in liability does what any business would do, which is reprice the product. But the law limits how fast Part D premiums can rise, so the repricing had to surface somewhere other than the premium.
What the $2,100 ceiling looks like in actual dollars
Run the arithmetic on a standard 2026 plan and the structure becomes obvious. The maximum allowable deductible is $615. Suppose your plan charges the full amount and then applies 25% coinsurance, which is the median rate stand-alone plans charge for preferred brand drugs.
You pay the first $615 yourself. From there you need another $1,485 of your own money to reach the $2,100 ceiling. At 25%, that $1,485 corresponds to $5,940 of drug spending. Add the deductible back and the total tab is $6,555. Once your prescriptions cross roughly $6,555 in a year, your share stops and the plan carries everything above it.
That single number explains most of the plan design you are about to shop through. Anyone whose annual drug spending lands near or above $6,555 is now a member the plan loses money on, and plans build formularies and cost sharing accordingly.
Your premium is being held down by a demonstration, not by the market
This is the part almost nobody mentions, and it is the reason the premium line looks reassuring. In July 2024, CMS launched a voluntary premium stabilization demonstration for stand-alone drug plans, then renewed it for a second year covering 2026. Nearly every plan sponsor signed up. The government subsidizes each member’s premium directly and caps how much any single plan may raise its premium year over year, and in exchange it absorbs more of the insurer’s downside risk.
The terms are tightening. In 2025 the subsidy knocked up to $15 a month off a member’s premium and no plan could raise its premium by more than $35. For 2026 the subsidy dropped to $10 and the allowable increase rose to $50. KFF notes that some plans took that full $50 even while the enrollment-weighted average fell.
So the flat premium is not evidence that the redesign is being absorbed painlessly. It is evidence that a temporary federal program is standing between the redesign and your monthly bill, on terms that get less generous each year. A demonstration is by definition not permanent.
Where the Medicare Part D 2026 changes actually landed: the deductible
Follow the deductible instead and the story is unmistakable. In 2024, only 23% of Medicare Advantage drug plan members faced any drug deductible at all. In 2025 it was 60%. In 2026 it is 82%. The enrollment-weighted average deductible in those plans went from $64 in 2024 to $228 in 2025 to $371 in 2026, a 481% increase in two years.
Stand-alone plans started from a higher base and moved less dramatically, but they moved in the same direction. Ninety-six percent of stand-alone plan members now face a deductible, and 78% face the full $615.
There is a revealing price attached to escaping it. Among stand-alone plan members, the 4% enrolled in a zero-deductible plan pay an average premium of $127 a month. The 78% in a plan charging the standard $615 deductible pay an average of $22. That is a gap of $105 a month, or $1,260 a year, to avoid a $615 deductible. You are paying just over two dollars for every dollar of deductible removed. Those richer plans do carry other advantages, but the pricing tells you the deductible is not really what you are buying.
Coinsurance quietly replaced copayments
Deductibles are the visible lever. The other one moved just as far and gets almost no attention. A copayment is a fixed dollar amount, so you know your cost before you reach the pharmacy counter. Coinsurance is a percentage of the drug’s price, which means your cost floats with a number you never see and the plan can renegotiate.
Virtually all stand-alone plan members now pay coinsurance rather than copays for preferred brand drugs, at a median rate of 25%, and every one of them pays coinsurance on non-preferred drugs, where the median runs 34%. Medicare Advantage drug plans are converging on the same approach fast. In 2025, 27% of their members faced coinsurance on preferred brands. In 2026 it is 56%. Specialty tier drugs, defined this year as those costing more than $950 a month, carry median coinsurance of 25% in stand-alone plans and 28% in Medicare Advantage plans.
The shift matters because coinsurance transfers price uncertainty to you. It also front-loads your spending, since a percentage of a large number is a large number, which is exactly when it collides with a deductible you now probably have.
Negotiated prices are the one place the underlying cost fell
Everything above is redistribution. The drug price negotiation program is the exception, because it changes what Medicare pays in the first place. Ten widely used drugs got negotiated prices that took effect January 1, 2026, including Eliquis at $231 against a $521 list price and Jardiance at $197 against $573. The discounts across the ten run from 38% to 79% off list, and CMS projects about $1.5 billion in out-of-pocket savings for beneficiaries in 2026.
If you take one of the ten, your coinsurance is calculated on the lower number, which is a real reduction rather than a shifted one. If you do not, the negotiation program has done nothing for your costs this year.
What to check before December 7
All of that adds up to a specific way to shop. Compare the annual total rather than the premium: twelve months of premium plus the deductible plus your expected coinsurance on the drugs you actually take. Then confirm each of your prescriptions is still on the formulary and still on the same tier, because tier placement moved a lot this year and a drug sliding from preferred to non-preferred can roughly double your share.
If your spending is likely to clear that $6,555 threshold, a plan with a higher premium and a smaller deductible may still win, since you will reach the $2,100 ceiling either way and the premium is the only variable left. If your spending is modest, the cap will never touch you and the deductible is your real cost. One more thing worth knowing: the Medicare Prescription Payment Plan lets you spread that out-of-pocket spending into level monthly installments across the year, which does not reduce the total but does keep a January refill from arriving all at once.
The Medicare Part D 2026 changes gave you a hard ceiling on annual drug spending, and that ceiling is worth having. Just read the rest of the plan knowing where the money went to pay for it. If cost sharing generally is the puzzle, our explainer on how your out-of-pocket maximum works covers the same machinery on the commercial side, and how the Social Security COLA is calculated explains the other number that determines what actually lands in your account.